Want to see PHVS full AI Analyst Report?
PHVS Stock Chart & Stats
$37.23
$0.91(2.74%)
At close: 4:00 PM EDT
$37.23
$0.91(2.74%)
Day’s Range― - ―
52-Week Range$21.02 - $43.25
Previous CloseN/A
Volume255.71K
Average Volume (3M)1.01M
Market Cap
$2.16B
Enterprise Value$1.99B
Total Cash (Recent Filing)$318.28M
Total Debt (Recent Filing)$673.73K
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Nov 18, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.70
Shares Outstanding69,863,686
10 Day Avg. Volume703,898
30 Day Avg. Volume1,013,435
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)5.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.18
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-18.70K
Enterprise Value/Ebitda-11.56
Forecast
1Y Price Target
$61.33Price Target Upside64.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 3 Clinical EfficacyThe strong Phase 3 prophylaxis result materially supports deucrictibant’s clinical profile and potential differentiation in HAE. Consistent efficacy across subgroups, significant secondary endpoints, and sustained protection improve the foundation for future regulatory and commercial execution.
Low Financial LeverageExtremely low leverage preserves financial flexibility while Pharvaris funds late-stage development and prepares for potential commercialization. Limited debt service obligations reduce balance-sheet pressure and leave more capacity for clinical programs, regulatory work, and other operating priorities.
Cash Runway For CommercializationA cash position extending runway into 2028 gives Pharvaris greater ability to complete regulatory processes, advance its pipeline, and prepare commercial infrastructure without an immediate financing deadline. This supports continuity through several important development and launch milestones.
Bears Say
Pre-revenue Business ModelThe absence of revenue means Pharvaris currently depends on successful development and regulatory approval before establishing recurring product sales. Until commercialization occurs, the company lacks operating revenue to offset research, clinical, regulatory, and pre-launch expenses.
Persistent Cash BurnLarge and persistent negative cash flow shows that operations continue to consume substantial funding as programs advance. Even with a strong cash position, ongoing burn can reduce financial flexibility over time and may require additional capital if commercialization or approvals take longer than planned.
Widening Losses And Equity ErosionDeep losses and persistently negative returns on equity indicate that Pharvaris is not yet converting invested capital into shareholder returns. Continued expense growth without revenue increases the risk that equity value is eroded before the lead program can generate commercial earnings.
Pharvaris News
PHVS FAQ
What was Pharvaris’s price range in the past 12 months?
Pharvaris lowest stock price was $21.02 and its highest was $43.25 in the past 12 months.
What is Pharvaris’s market cap?
Pharvaris’s market cap is $2.16B.
When is Pharvaris’s upcoming earnings report date?
Pharvaris’s upcoming earnings report date is Nov 18, 2026 which is in 27 days.
How were Pharvaris’s earnings last quarter?
Pharvaris released its earnings results on Aug 12, 2026. The company reported -$0.786 earnings per share for the quarter, missing the consensus estimate of -$0.735 by -$0.052.
Is Pharvaris overvalued?
According to Wall Street analysts Pharvaris’s price is currently Undervalued.
Does Pharvaris pay dividends?
Pharvaris does not currently pay dividends.
What is Pharvaris’s EPS estimate?
Pharvaris’s EPS estimate is -0.81.
How many shares outstanding does Pharvaris have?
Pharvaris has 69,863,686 shares outstanding.
What happened to Pharvaris’s price movement after its last earnings report?
Pharvaris reported an EPS of -$0.786 in its last earnings report, missing expectations of -$0.735. Following the earnings report the stock price went up 5.927%.
Which hedge fund is a major shareholder of Pharvaris?
Currently, no hedge funds are holding shares in PHVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharvaris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.33 (64.74% Upside)
$61.33 (64.74% Upside)
Blogger Sentiment
Bullish
PHVS Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 81.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.80%
12-Months-Change
Fundamentals
Return on Equity
-61.24%
Trailing 12-Months
Asset Growth
52.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pharvaris
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
PHVS Stock 12 Month Forecast
Average Price Target
$61.33
▲(64.74% Upside)
Technical Analysis
Ownership Overview
2.33% Insiders
7.58% Mutual Funds
0.02% Other Institutional Investors
88.67% Public Companies and
Individual Investors